Andrew Kwong

Aaron Tsumura3
Martina Sanlorenzo3
Igor Vujic3
Christian Posch3
Klemens Rappersberger3
3Aaron Tsumura
3Martina Sanlorenzo
3Igor Vujic
3Christian Posch
3Klemens Rappersberger
Learn More
  • Igor Vujic, Martina Sanlorenzo, Christian Posch, Rosaura Esteve-Puig, Adam J. Yen, Andrew Kwong +4 others
  • 2015
Attempts to directly block the mutant neuroblastoma rat sarcoma oncogene (NRAS) protein, a driving mutation in many cancer types, have been unsuccessful. Current treatments focus on inhibition of different components of NRAS' two main downstream cascades: PI3K/AKT/mTOR and MAPK. Here we test a novel dual therapy combination of metformin and trametinib on a(More)
  • Igor Vujic, Christian Posch, Martina Sanlorenzo, Adam J. Yen, Aaron Tsumura, Andrew Kwong +5 others
  • 2014
Oncogenic mutations in the Neuroblastoma Rat Sarcoma oncogene (NRAS) are frequent in melanoma, but are also found in several other cancer types, such as lung cancer, neuroblastoma and colon cancer. We designed our study to analyze changes in NRAS mutant tumor cells derived from malignancies other than melanoma. A variety of small molecule inhibitors as well(More)
  • Igor Vujic, Martina Sanlorenzo, Rosaura Esteve-Puig, Marin Vujic, Andrew Kwong, Aaron Tsumura +6 others
  • 2016
Oncogenic NRAS mutations are frequent in melanoma and lead to increased downstream signaling and uncontrolled cell proliferation. Since the direct inhibition of NRAS is not possible yet, modulators of NRAS posttranslational modifications have become an area of interest. Specifically, interfering with NRAS posttranslational palmitoylation/depalmitoylation(More)
  • 1